A great place to do great things: Developing game-changing technology at Abbott

AbbottScience has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized Abbott on its Top Employers list, which is based on an evaluation of 23 characteristics including financial strength, easy adaptation to change, and a research-driven environment.

At Abbott, scientists develop life-changing technologies that help people live their best lives through good health. From freeing people with diabetes from routine finger sticks(1), to building a cardiac device to save lives, to hunting for new virus mutations, every day Abbott employees are doing work that matters.

"Abbott's diverse businesses and product lines open up exciting career opportunities for our scientists across a range of technologies," said John Frels, Ph.D., chair of Abbott's Scientific Governing Board, which oversees the company's senior scientific career track.

"We strive to foster a culture of innovation and collaboration within our teams and in our work with others to gain fresh perspectives and further inspire our scientists to continue to push the boundaries on scientific advancements. This contributes to a strong, vibrant and fulfilling environment for scientists to develop their careers - and supports Abbott's long, successful legacy of scientific achievement and game-changing technology."

Our spirit of innovation and relentless focus on pushing the frontiers of science have allowed our company to thrive for more than 125 years. Today, we're working tirelessly to carry on that great legacy and to address some of healthcare's greatest challenges.

Some of Abbott's latest breakthroughs include:

  • A unified family of innovative next-generation diagnostics systems across lab disciplines that offer more efficiency, flexibility and confidence to health systems, and better help doctors and nurses get the results they need to improve decision-making and patient care.
  • Our revolutionary diabetes technology that replaces blood glucose monitoring, freeing people with diabetes from the pain and hassles of routine fingersticks.
  • Pioneering neuromodulation technology that can transform quality of life for many people who are otherwise unable to find relief from their chronic pain, while also reducing or stabilizing opioid use among patients battling chronic pain conditions.
  • A first-of-its-kind cardiac device that has transformed the treatment of certain kinds of mitral regurgitation (MR) for people who are too frail for open-heart surgery or those who are not candidates for surgery.
  • Groundbreaking research that has helped bring infant formula closer than ever to breast milk.

About the 2017 Science survey
The 2017 Science survey sought to identify the companies with the best reputations as employers. The findings are based on 6,950 completed surveys from readers of Science and other survey invitees. Survey respondents came from North America (65%), Europe (25%) and Asia/Pacific Rim (7%); 94% work in biotechnology, biopharmaceutical and pharmaceutical companies. Here's a complete list of the rankings, which also are available in the Oct. 20, 2017 print edition of Science.

About Abbott
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life.

Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

1. A finger prick test using a blood glucose meter is required during times of rapidly changing glucose levels when interstitial fluid glucose levels may not accurately reflect blood glucose levels or if hypoglycaemia or impending hypoglycaemia is reported by the system or when symptoms do not match the system readings.

Most Popular Now

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...